Evidence map›Paper›PMID 42779047›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Distinct single-nucleus RNA-seq changes among non-neuronal cells in ADNC, LATE-NC, and mixed pathologies.

Qi Qiao, Yuriko Katsumata, Hsin-Yu Lai, Kevin Z Lin, Steven A Claas, Mariano I Gabitto, Josh M Morganti, Peter T Nelson, Shubhabrata Mukherjee, David W Fardo

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qi QiaoDepartment of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky, USA.
Yuriko KatsumataSanders-Brown Center on Aging and Alzheimer's Disease Research Center, University of Kentucky, Lexington, Kentucky, USA.
Hsin-Yu LaiAllen Institute for Brain Science, Seattle, Washington, USA.
Kevin Z LinDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Steven A ClaasDepartment of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky, USA.
Mariano I GabittoAllen Institute for Brain Science, Seattle, Washington, USA.
Josh M MorgantiSanders-Brown Center on Aging and Alzheimer's Disease Research Center, University of Kentucky, Lexington, Kentucky, USA.
Peter T NelsonSanders-Brown Center on Aging and Alzheimer's Disease Research Center, University of Kentucky, Lexington, Kentucky, USA.
Shubhabrata MukherjeeDepartment of Medicine, University of Washington, Seattle, Washington, USA.
David W FardoDepartment of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky, USA.ORCID https://orcid.org/0000-0002-7207-4696

Funding

Topographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomicsU19AG060909 · NIA · ALLEN INSTITUTE · PI Jennie Leigh Close, Michael Hawrylycz · 2020 to 2026
$83.6M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Genetic Architecture of Pure Alzheimer's Disease and Mixed PathologyR01AG082730 · NIA · UNIVERSITY OF WASHINGTON · PI David William Fardo, Shubhabrata Mukherjee · 2023 to 2026
$4.0M
Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology DementiaR01AG082339 · NIA · UNIVERSITY OF KENTUCKY · PI David William Fardo, PETER T. NELSON · 2026 to 2026
$600k
Alzheimer's Disease Research Center P30 AG066509Alzheimer's Disease Research Center P50 AG005136Alzheimer's Disease Research Center U01 AG006781Alzheimer's Disease Research Center U19 AG066567NIA NIH HHS P30 AG066509NIA NIH HHS P30AG066509NIA NIH HHS P30 AG072946NIA NIH HHS P50 AG005136NIA NIH HHS P50AG005136NIA NIH HHS R01 AG082339NIA NIH HHS R01AG082339NIA NIH HHS R01 AG082730NIA NIH HHS R01AG082730NIA NIH HHS U01 AG006781NIA NIH HHS U01AG006781NIA NIH HHS U19 AG060909NIA NIH HHS U19AG060909NIA NIH HHS U19 AG066567NIA NIH HHS U19AG066567NIH R01AG082730University of Kentucky Alzheimer's Disease Core Center
6 · The paper itself

Abstract

introductionLimbic-predominant age-related transactive response DNA binding protein 43 kDa encephalopathy neuropathological change (LATE-NC) frequently co-occurs with Alzheimer's disease neuropathologic change (ADNC), complicating classification. Cell type-specific molecular features distinguishing LATE-NC-dominant, ADNC-dominant, and mixed LATE-NC and ADNC pathology remain incompletely characterized.

methodsWe analyzed single-nucleus RNA sequencing data from the Seattle Alzheimer's Disease Brain Cell Atlas consortium, focusing on non-neuronal cells in the middle temporal gyrus (MTG). Donors were stratified into LATE-NC dominant, ADNC dominant, and mixed LATE-NC and ADNC. Differential expression and gene set enrichment analyses were performed across glial and vascular cell supertypes.

resultsDistinct transcriptional patterns differentiated pathologies. Astrocytes, microglia, and oligodendrocytes exhibited differential expression between LATE-NC- and ADNC-dominant cases. Representative genes and pathways highlighted these distinctions, with LATE-NC dominant showing enrichment in signaling and RNA regulation, ADNC dominant in mitochondrial dysfunction, and mixed pathology in translational dysregulation and lipid remodeling, suggesting a distinct biological state. DISCUSSION: Findings highlight biological heterogeneity and non-neuronal molecular features relevant to disease classification and future research. CLINICAL TRIAL REGISTRATION INFORMATION: Not applicable. This study is a secondary analysis of publicly available Seattle Alzheimer's Disease Brain Cell Atlas (SEA-AD) data.

Indexed as

Alzheimer DiseaseBrain DiseasesAgedAged, 80 and overAstrocytesBrainDementiaFemaleHumansMaleMicrogliaNeurogliaRNA-SeqTDP-43 ProteinopathiesTemporal Lobeaging brainAlzheimer's diseasecomorbid neuropathologydifferential gene expressionglial cell typeslimbic‐predominant age‐related transactive response DNA binding protein 43 kDa encephalopathysingle‐nucleus RNA sequencingtranscriptomics

Identifiers

PMID42779047
PMCPMC13601766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.